Cognition Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$16.8MTTM through 30 Jun 2026
Free Cash Flow -$17.7MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-50.8%ROE
-43.1%ROA
Balance Sheet Health
Debt / Equity0.01x
Current Ratio7.03x
Net Debt-$33.8Mnet cash position
Cash & Equivalents$34M
Quality Metrics
Altman Z-Score-0.01
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$0.17TTMFY2025: $-0.32
Dividend
No dividend
Capital Allocation
R&D Spend$26.1M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.